Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study

AIMS/HYPOTHESIS: 0.05). Retinal vascular status assessed using artificial intelligence remained stable throughout follow-up in both eyes (nominal p=0.710 and p=0.563, respectively). CONCLUSIONS/INTERPRETATION: The MiniMed 780G system appears effective for glycaemic management and safe for use in older adults with long-standing type 1 diabetes and a high burden of comorbidities. A non-statistically significant numerical tendency (p>0.05) in the improvement of vascular function that requires further confirmation was also observed. TRIAL REGISTRATION: ClinicalTrials.gov NCT06207838.